Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition from Remodulin to Oral Treprostinil in PAH
NCT01588405Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2012
- Primary completion
- Jul 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Apr 2012; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01588405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588405.